Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Arne Leth is active.

Publication


Featured researches published by Arne Leth.


Bone and Mineral | 1988

Iliac crest biopsy in longitudinal therapeutic trials of osteoporosis.

Jan Pødenphant; B.J. Riis; Julia S. Johansen; Arne Leth; Claus Christiansen

Changes in tetracycline-labelled iliac crest biopsies taken before and after 1 year of treatment with nandrolone decanoate + calcium, 17 beta-estradiol + norethisterone acetate + calcium or placebo were compared with changes in plasma bone Gla protein (pBGP), serum alkaline phosphatase (sAP), whole body retention (WBR) of Technetium-99m-diphosphonate [( 99mTc]DP) and bone mineral content (BMC) of the forearm. Based on a comparison between biopsy and noninvasive results, as well as on evaluation of the variation in the groups, certain guidelines for the use of bone histomorphometry in longitudinal therapeutic trials are suggested. It is proposed that bone biopsy is not used to monitor changes in amount of bone and that evaluation of changes in biopsy evaluated bone turnover is only attempted when the groups are large.


Clinical Pharmacology & Therapeutics | 1983

Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients.

Ulrik Gerner Svendsen; Hans Ibsen; Sten Rasmussen; Arne Leth; Meta Damkjær Nielsen; Harriet Dige-Petersen; Jørn Giese

Total body potassium content, plasma potassium concentration, blood pressure, and plasma concentrations of renin, angiotensin II, and aldosterone were measured in patients with essential hypertension after a run‐in period of 8 wk on a regimen of hydrochlorothiazide (median dosage 75 mg/day). Patients were then randomly assigned to continued hydrochlorothiazide therapy (group I) or to receive adjunctive treatment with amiloride (group II, median dosage 15 mg/day or 5 mg per 25 mg hydrochlorothiazide) for the following 3 mo. There were no changes in group I patients during 3 mo on hydrochlorothiazide in plasma potassium, total body potassium content, or the renin‐angiotensin‐aldosterone system. Blood pressure was also unchanged. In group II patients addition of amiloride to hydrochlorothiazide induced a rise in plasma and total body potassium of approximately 15% and 4%. The potassium‐retaining effect was maintained throughout the 12‐wk period, although the maximal changes were observed after 8 wk of treatment. Supine blood pressure did not change, but there was a significant decrease in standing systolic blood pressure. There was a marked rise in plasma concentrations of renin, angiotensin II, and aldosterone.


European Journal of Clinical Pharmacology | 1986

Effects of combined therapy with amiloride and hydrochlorothiazide on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in hypertensive patients

Ulrik Gerner Svendsen; Hans Ibsen; Sten Rasmussen; Arne Leth; Meta Damkjær Nielsen; Harriet Dige-Petersen; Jørn Giese

SummaryAfter a run-in period of 8 weeks on a regimen of hydrochlorothiazide (HCT, median dosage 75 mg/day), patients with essential hypertension were randomly allocated to continued hydrochlorothiazide therapy (Group I) or additional treatment with amiloride (Group II, median dosage 15 mg/day, or 5 mg per 25 mg hydrochlorothiazide) for the following 12 weeks. Thereafter all the patients were changed to treatment with a fixed combination tablet containing 5 mg amiloride and 50 mg hydrochlorothiazide (Moduretic), keeping the thiazide dosage unchanged for an additional 12 weeks. In Group I patients there was no change in plasma potassium, total body potassium content or the renin-angiotensin-aldosterone system during the 12 weeks on HCT. When the treatment was changed to Moduretic, significant increases were found of 10% in plasma potassium and 3% in total body potassium content. No important stimulation of the renin-angiotensin-aldosterone system was found. In Group II patients addition of an average of 15 mg amiloride to the hydrochlorothiazide treatment led to significant increases in plasma potassium and total body potassium content of approximately 15% and 4%, respectively. There was also a significant increase in the plasma concentrations of renin, angiotensin II and aldosterone. Reducing the average dose of amiloride to 7.5 mg/day by use of Moduretic did not lead to decrease in plasma potassium or total body potassium content. Plasma concentrations of renin, angiotensin II, and aldosterone were decreased, but the individual changes varied markedly and no significant overall change was found.


Acta Medica Scandinavica | 2009

Cardiac rupture in acute myocardial infarction. A review of 72 consecutive cases.

Sten Rasmussen; Arne Leth; Erik Kjøller; Asger Pedersen


Acta Medica Scandinavica | 2009

Bumetanide, a new potent diuretic. A clinical evaluation in congestive heart failure.

Knud H. Olesen; Bjarne Sigurd; Eva Steiness; Arne Leth


Journal of Bone and Mineral Research | 2009

Bone turnover in spinal osteoporosis

Jan Pødenphant; Julia S. Johansen; Karsten Thomsen; B.J. Riis; Arne Leth; Claus Christiansen


Acta Medica Scandinavica | 2009

The prognosis in Ebstein's disease of the heart. Long-term follow-up of 22 patients.

J. Fischer Hansen; Arne Leth; S. Dorph; Alf Wennevold


Acta Medica Scandinavica | 2009

Acute myocardial infarction complicated by third degree atrioventricular block treated with temporary pacemaker. Hospital and long-term survival in 57 patients.

Arne Leth; Jørgen Fischer Hansen; Jørgen Meibom


Acta Medica Scandinavica | 2009

Converting enzyme inhibition in mild and moderate essential hypertension. I. Acute effects on blood pressure, the renin-angiotensin system and blood bradykinin after a single dose of captopril.

Sten Rasmussen; Arne Leth; Hans Ibsen; Meta Damkjær Nielsen; Finn Erland Nielsen; J. Giese


Acta Medica Scandinavica | 2009

Testing of equipment for home blood pressure reading.

Arne Leth; Bjørn Christau; Peter Schnohr; Niels Eske Bruun; Lars Møller

Collaboration


Dive into the Arne Leth's collaboration.

Top Co-Authors

Avatar

Hans Ibsen

Copenhagen University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

B.J. Riis

University of Copenhagen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jan Pødenphant

Copenhagen University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jørgen Fischer Hansen

Copenhagen University Hospital

View shared research outputs
Top Co-Authors

Avatar

Jørn Giese

University of Copenhagen

View shared research outputs
Researchain Logo
Decentralizing Knowledge